San Francisco, CA, United States of America

Kavoos Kolahdouzan

This inventor holds 7 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Gilead Sciences, Inc.. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kavoos Kolahdouzan. Retrieved from https://idiyas.com/inventor/kavoos-kolahdouzan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 100.0

 

Average Co-Inventor Count = 13.2

ph-index = 3

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2023-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Kavoos Kolahdouzan

Introduction: Kavoos Kolahdouzan, a visionary inventor based in San Francisco, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Kavoos Kolahdouzan holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and creativity.

Career Highlights: With a background in engineering and a passion for problem-solving, Kavoos Kolahdouzan has led numerous successful projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Kavoos Kolahdouzan has collaborated with leading research institutions, universities, and tech companies to bring his ideas to life and create tangible solutions for complex challenges.

Conclusion: Inventor Kavoos Kolahdouzan's relentless pursuit of innovation and his commitment to pushing the boundaries of what is possible make him a true pioneer in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…